Establishing Targets for Hypertension Control in Patients with Comorbidities
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Most current guidelines recommend tighter blood pressure (BP) control in hypertensive patients with comorbidities. These recommendations are based on epidemiologic data indicating that cardiovascular risk increases at lower BP levels in hypertensive patients with comorbidities than in those without comorbidities. Hypertension guidelines usually reflect outcomes from previous studies, but current recommendations for patients with comorbidities have preceded the evidence. We review recent studies investigating whether these new targets can be achieved, whether they are well tolerated, and whether they positively affect the outcomes. The results of the few current studies about outcomes in lower BP target groups are either negative or somewhat—but not decidedly—positive. There is a need for new trials designed to evaluate the validity of current recommendations for tighter BP control in hypertensive patients with comorbidities. Additionally, existing data from published trials could be reanalyzed to provide further clarification.
- Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572. CrossRef
- •• Cutler JA, Sorlie PD, Wolz M, et al.: Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008, 52:818–827. The age-standardized prevalence of hypertension between the third National Health and Nutrition Examination Survey (1988–1994) and the 1999–2004 National Health and Nutrition Examination Survey increased from 24.4% to 28.9% (P < 0.001), with the largest increases among non-Hispanic women. CrossRef
- Chobanian AV: The Hypertension Paradox—More uncontrolled disease despite improved therapy. N Engl J Med 2009, 361:878–887. CrossRef
- •• Plantinga LC, Miller ER 3 rd, Stevens LA, et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team: Blood pressure control among persons without and with chronic kidney disease. US trends and risk factors 1999–2006. Hypertension 2009, 54:47–56. Although BP control in the general population has increased over time, uncontrolled blood pressure remains highly prevalent, especially in patients with CKD and in nonwhites, older persons, and women. CrossRef
- Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21–e181. CrossRef
- Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913. CrossRef
- Neal B, MacMahon S: The World Health Organization–International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Curr Hypertens Rep 1999, 1:346–356. CrossRef
- Lawes CMM, Vander Horn S, Rodgers A: Global burden of blood pressure related disease, 2001. Lancet 2008, 371:1513–1518. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252. CrossRef
- Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105–1187. CrossRef
- Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993,16:434–444. CrossRef
- American Diabetes Association Standards of Medical Care in Diabetes—2010: Diabetes Care 2010, 33(Suppl 1):S11–S61.
- •• Cushman WC, Evans GW, Byington RP, et al.; The ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575–1585. Intensive antihypertensive therapy in patients with type 2 diabetes targeting SBP to less than 120 mm Hg was accompanied by more serious adverse events than standard therapy targeting to SBP less than 140 mm Hg. There were no significant between-group differences in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes), but there was a significant reduction in strokes. CrossRef
- ACCORD Study Group, Buse JB, Bigger JT, et al.: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i–33i. CrossRef
- Cushman WC, Grimm RH Jr, Cutler RA, et al.; ACCORD Study Group: Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99:44i–55i. CrossRef
- Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3–10. CrossRef
- Opie LH, Schall R: Old antihypertensives and new diabetes. J Hypertens 2004, 22:1453–1458. CrossRef
- Cruickshank JM: Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther 2000, 14:373–379. CrossRef
- Messerli FH, Panjrath GS: The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009, 54:1827–1834. CrossRef
- Roy M, Mahmood N, Rosendorff C: Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease. Curr Atheroscler Rep 2010, 12:134–139. CrossRef
- Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829–840. CrossRef
- • Weir MR, Yeh F, Silverman A, et al.: Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. J Clin Hypertens (Greenwich) 2009, 11:540–548. The study, involving type 2 diabetic Native Americans, investigated in the effect of lowering blood pressure to 115/75 mm Hg and lowering LDL cholesterol to 70 mg/dL, compared with the standard goal of blood pressure of 130/80 mm Hg and 100 mg/dL LDL cholesterol. There was a larger reduction of the carotid intima-media thickness and left ventricular mass in the strict-target group, but no significant difference was found in cardiovascular events. CrossRef
- Lloyd-Jones DM, Evans JC, Levy D: Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005, 294:466–472. CrossRef
- Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115:2761–2788. CrossRef
- Izzo JL Jr, Gradman AH: Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 2004, 88:1257–1270. CrossRef
- Jamerson K, Weber MA, Bakris GL, et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417–2428. CrossRef
- Verdecchia P, Staessen JA, Angeli F, et al; Cardio-Sis Investigators: Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009, 374:525–533. CrossRef
- JATOS Study Group: Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008, 31:2115–2127. CrossRef
- U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End Stage Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health; 2005.
- Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al.: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073–2081. CrossRef
- Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001, 161:1207–1216. CrossRef
- Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(Suppl 1):S1–S290.
- Sarafidis PA, Bakris GL: Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749–1757. CrossRef
- de Galan BE, Perkovic V, Ninomiya T, et al.: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883–892. CrossRef
- •• Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173–1181. The percentage of patients achieving the goal of less than 130/80 mm Hg was similar in the two treatment groups (37.2% vs 39.2%). Despite the similar degree of BP control, a greater reduction in the progression of CKD was seen in the combination benazepril plus amlodipine group than in the benazepril plus hydrochlorothiazide group. CrossRef
- Praga M, Andrade CF, Luño J, et al.: Antiproteinuric amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003, 18:1806–1813. CrossRef
- Bakris GL, Toto RD, McCullough PA, et al.; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008, 73:1303–1309. CrossRef
- Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889–896. CrossRef
- Kesarwani M, Perez A, Lopez VA, et al.: Cardiovascular comorbidities and blood pressure control in stroke survivors. J Hypertens 2009, 27:1056–1063. CrossRef
- Yusuf S, Diener HC, Sacco RL, et al.: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225–1237. CrossRef
- Arima H, Chalmers J, Woodward M, et al.: Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006, 24:1201–1208. CrossRef
- Davis G, Donnan S, MacMahon B, et al.: The effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke 2004, 35:116–121.
- The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174–1183. CrossRef
- The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980, 1(8181):1261–1267.
- Establishing Targets for Hypertension Control in Patients with Comorbidities
Current Hypertension Reports
Volume 12, Issue 6 , pp 465-473
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Blood pressure
- Cardiovascular risk
- Clinical trials
- Kidney disease
- Industry Sectors
- Author Affiliations
- 2. Hypertension Program, Hospital de Clinicas J. de San Martin, University of Buenos Aires School of Medicine, Buenos Aires, Argentina
- 1. University of Michigan, 2368 Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI, 48109, USA